NLS Pharmaceutics Ltd. (NLS), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders, and Kadimastem Ltd., a clinical-stage biotechnology company developing cell therapy solutions for diseases such as ALS and diabetes, have announced the signing of a Memorandum of Understanding (MoU) between Kadimastem and TargetGene Biotechnologies Ltd. (TargetGene), a pioneer in precision gene-editing technologies.
The collaboration will combine Kadimastem’s proprietary cell therapy platforms — including AstroRx for ALS and IsletRx for diabetes — with TargetGene’s next-generation DNA-guided gene-editing platform, which enables precise and multiplexed genome modifications with minimal off-target effects.
The initiative is expected to continue under the combined company, NewCelX, following the anticipated merger between NLS and Kadimastem.
Under the terms of the MoU, the partners will jointly develop and optimize gene-edited cell therapy products designed to improve therapeutic performance, safety, and stability. The collaboration aims to accelerate the creation of curative, scalable, and commercially viable treatments for complex diseases.
The agreement also establishes a framework for joint R&D activities, technology exchange, and potential licensing opportunities, laying the groundwork for a long-term strategic alliance.
Yoel Shiboleth, CEO of TargetGene, said:
“Our collaboration with Kadimastem represents an exciting step forward in cell-based medicine. By combining TargetGene’s precision gene-editing technology with Kadimastem’s stem cell platforms, we can push the boundaries of regenerative medicine — creating safer, more effective therapies for long-term patient benefit.”
Prof. Michel Revel, Chief Scientist and Founder of Kadimastem, commented:
“Integrating precise gene editing with our stem-cell–derived therapeutic cells opens new horizons in regenerative medicine. This partnership allows us to design cells with enhanced biological properties, improving survival, function, and therapeutic potential in ALS and other diseases.”
Ronen Twito, Executive Chairman and CEO of Kadimastem, added:
“This collaboration with TargetGene marks a major step in Kadimastem’s mission to develop curative, cell-based therapies. By uniting our stem cell platforms with TargetGene’s gene-editing tools, we aim to create smarter, more resilient cells for better patient outcomes.”
Kadimastem Ltd. is a clinical-stage cell therapy company developing “off-the-shelf,” allogeneic cell products based on human embryonic stem cell (hESC) technology. Its lead product, AstroRx, is in clinical development for ALS and preclinical studies for other neurodegenerative disorders.
NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and related indications.
TargetGene Biotechnologies Ltd. is an Israeli biotechnology company pioneering gene-editing innovations. Its proprietary TGEE platform and genetic-circuit “rewiring” system are protected by a broad patent portfolio, supporting the company’s position as a leader in precision genome engineering.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!